Atrium Therapeutics, Inc. (RNA) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -31.14M | -19.25M | -156.17M | -199.67M | -124.83M | -99.87M | -65.61M | -65M | -70.38M | 16.5M | -36.79M | -49.81M |
| Operating CF Margin % | -158.61% | -2241.21% | -1251.89% | -5190.17% | -7935.73% | -3359.27% | -2808.86% | -3178.68% | -1986.45% | 752.44% | -1305.57% | -2150.56% |
| Operating CF Growth % | 75.05% | 80.72% | -138.01% | -207.16% | -77.36% | -705.24% | -78.35% | -30.51% | -43.73% | 142.11% | -15.12% | -40.12% |
| Net Income | -16.63M | -29.14M | -174.44M | -157.31M | -115.77M | -102.26M | -80.4M | -70.79M | -68.86M | -60.44M | -52.36M | -47.02M |
| Depreciation & Amortization | 151K | 122K | 1.06M | -7.82M | 785K | 738K | 710K | 687K | 641K | 615K | 566K | 529K |
| Stock-Based Compensation | 0 | 3.55M | 19.02M | 17.66M | 17.74M | 14.15M | 14.09M | 12.81M | 10.31M | 9.85M | 9.82M | 9.45M |
| Deferred Taxes | 0 | 34K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8.72M | -2.97M | -2.84M |
| Other Non-Cash Items | 13.05M | 416K | -1.29M | 5.98M | -4.33M | -6.34M | -6.03M | -3.65M | -2.13M | 6.3M | 734K | 732K |
| Working Capital Changes | -27.71M | 5.76M | -516K | -58.17M | -23.24M | -6.16M | 6M | -4.06M | -10.34M | 68.9M | 7.41M | -10.66M |
| Change in Receivables | -15M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -3.59M | 3.81M | 5.78M | 10.67M | -15.34M | 20.46M | 8.68M | -2.5M | 2.58M | 2.36M | 228K | -1.97M |
| Cash from Investing | -2.1M | -879K | -587.93M | 185.49M | 157.19M | -64.17M | -482.41M | -274.87M | -32.75M | 51.04M | -31.48M | 46.05M |
| Capital Expenditures | -2.1M | -879K | -712K | -3.34M | -3.75M | -3.92M | -1.7M | -531K | -915K | -863K | -923K | -622K |
| CapEx % of Revenue | 10.69% | 102.33% | 5.71% | 86.9% | 238.59% | 131.72% | 72.95% | 25.97% | 25.83% | 39.35% | 32.75% | 26.86% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -51.9M | 30.56M | -46.67M |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -3.17M | 0 | 0 | 0 | 0 | 0 | 0 | 51.9M | -30.56M | 46.67M |
| Cash from Financing | 301.5M | 20.13M | 850.37M | 3.77M | 1.94M | 13.72M | 342.46M | 446.72M | 389.44M | 31.89M | 40K | 38.97M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 837.42M | 3.77M | 1.94M | -141.9M | 465.15M | 433.05M | 244.24M | 31.89M | 40K | 38.11M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 301.5M | 20.13M | 12.95M | 0 | 0 | 155.62M | -122.69M | 13.68M | 145.2M | 0 | 0 | 866K |
| Net Change in Cash | 267.85M | 0 | 106.25M | -10.29M | 34.34M | -150.32M | -205.56M | 106.85M | 286.32M | 99.43M | -68.23M | 35.21M |
| Free Cash Flow | -33.24M | -20.13M | -160.06M | -203.01M | -128.58M | -103.79M | -67.32M | -65.53M | -71.3M | 15.64M | -37.71M | -50.43M |
| FCF Margin % | -169.29% | -2343.54% | -1283.05% | -5277.07% | -8174.32% | -3490.99% | -2881.81% | -3204.65% | -2012.28% | 713.09% | -1338.33% | -2177.42% |
| FCF Growth % | 74.15% | 80.6% | -137.76% | -209.77% | -80.35% | -763.68% | -78.5% | -29.95% | -40.38% | 139.06% | -18.4% | -36.78% |
| FCF per Share | -1.94 | -1.18 | -1.16 | -1.57 | -0.99 | -0.81 | -0.55 | -0.61 | -0.82 | 0.21 | -0.51 | -0.71 |
| FCF Conversion (FCF/Net Income) | 1.87x | 0.40x | 0.90x | 1.27x | 1.08x | 0.98x | 0.82x | 0.92x | 1.02x | -0.27x | 0.70x | 1.06x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |